Sana Biotechnology SANA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's accrued expenses and other liabilities?
- Sana Biotechnology (SANA) reported accrued expenses and other liabilities of -$7.09M in Q1 2026.
- How has Sana Biotechnology's accrued expenses and other liabilities changed year-over-year?
- Sana Biotechnology's accrued expenses and other liabilities increased by 20.2% year-over-year, from -$8.89M to -$7.09M.